Q4, 2019, 2020 Earnings Estimates for Pacira Biosciences Raised
3:06AM ET 11/09/2019 MT NewswiresConsensus estimates for Q4 ending December 31, 2019, and the full year forecasts for 2019 and 2020 for the years ending on December 31 for Pacira...
Quotes Snapshot > PCRX
Pacira Biosciences Inc PCRX:NASDAQ
Last Price$45.87Cboe Previous Close - Real-Time Last Sale as of 3:59PM ET 12/06/19
Cboe Real-Time Quotes
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$42.47 (100)
Ask (Size)$47.94 (100)
Day Low / HighN/A - N/A
Volume306.5 K
Read more news Recent News
2019 Estimate for Pacira Biosciences Scaled Up but 2020 Earnings Number Scaled Down
2:56AM ET 11/08/2019 MT NewswiresThe full year forecasted earnings estimates for 2019 and 2020 for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 42.62) have been changed. The...
Pacira BioSciences Q3 Non-GAAP EPS Beats, Revenue Just Short of Expectations
10:03AM ET 11/07/2019 MT NewswiresPacira BioSciences (PCRX) on Thursday reported Q3 non-GAAP EPS of $0.48, compared with $0.31 a year earlier and the Capital IQ consensus forecast of $0.33....
Analyst Actions: BTIG Research Initiates Coverage on Pacira Pharmaceuticals With Buy Rating, $56 PT
9:33AM ET 11/06/2019 MT NewswiresPacira Pharmaceuticals' (PCRX) average rating among analysts is a hold, with an average price target of $54. Price: 43.30, Change: +1.08, Percent Change:...
View all Commentary and Analysis
ViacomCBS, Amazon's AWS Event And Conference Blitz (Stocks To Watch Podcast)
7:30AM ET 12/01/2019 Seeking AlphaStocks To Watch: ViacomCBS, Amazon's AWS Event And Conference Blitz
8:39AM ET 11/30/2019 Seeking AlphaTracking John Paulson's Paulson & Company Portfolio - Q3 2019 Update
8:01PM ET 11/28/2019 Seeking AlphaPacira BioSciences, Inc.'s (PCRX) CEO Dave Stack on Q3 2019 Results - Earnings Call Transcript
3:21PM ET 11/07/2019 Seeking AlphaCompany Profile
Business DescriptionPacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ. View company web site for more details
| Address | 5 Sylvan Way Parsippany, New Jersey 07054 |
| Phone | +1.973.254.3560 |
| Number of Employees | 518 |
| Recent SEC Filing | 12/06/2019 CT ORDER |
| Chairman, Chief Executive & Operating Officer | David M. Stack |
| President | Max Reinhardt |
| Chief Financial Officer | Charles A. Reinhart |
| Vice President-Research & Development | Vladimir Kharitonov |
Company Highlights
| Price Open | $45.65 |
| Previous Close | $45.87 |
| 52 Week Range | $34.64 - 49.50 |
| Market Capitalization | $1.9 B |
| Shares Outstanding | 41.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Other | Next Earnings Announcement | 02/27/2020 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 1.1K |
| Earnings per Share | $0.32 |
| Beta vs. S&P 500 | N/A |
| Revenue | $337.3 M |
| Net Profit Margin | 0.55% |
| Return on Equity | 0.65% |
Analyst Ratings as of 11/04/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |